Bavarian Nordic receives approval for smallpox vaccine from Health Canada

Bavarian Nordic said on Friday that it received a Notice of Compliance from Health Canada for IMVAMUNE, a smallpox vaccine to be used in public health emergencies.

IMVAMUNE is for people 18 years of age and older who are not able to receive a standard smallpox vaccine, including people with immune deficiencies and skin disorders.

Health Canada is the second government agency to approve the vaccine for use; it was previously approved by the European Commission where it is marketed under the name IMVANEX.

"The approval of IMVAMUNE in Canada continues our track record of successfully working with governments to address their biological preparedness requirements," Anders Hedegaard, the president and CEO of Bavarian Nordic, said.

Bavarian Nordic has collaborated with the Canadian government since 2008 in order to address Canada's preparedness for biological threats. The company was awarded a contract to supply 20,000 doses of the smallpox vaccine to the armed forces and received a replacement order in 2012.

"We have partnered with the U.S. government for more than a decade on the development of our smallpox vaccine and we are delighted that Canada now leverages on this successful partnership," Hedegaard said. "This approval provides further validation of our MVA-BN vaccine technology platform which we have successfully developed and commercialized."